INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Mar 02, 2017 |
VP, Controller
Trans History: 306
|
VP, Controller | Form 3 | Initial Statement of Beneficial Ownership of Securities | -- | -- | -- |
| Mar 02, 2017 |
VP, Controller
Trans History: 306
|
VP, Controller | Form 3 | Initial Statement of Beneficial Ownership of Securities | -- | -- | -- |
| Mar 02, 2017 |
VP, Controller
Trans History: 306
|
VP, Controller | Form 3 | Initial Statement of Beneficial Ownership of Securities | -- | -- | -- |
| Mar 02, 2017 |
VP, Controller
Trans History: 306
|
VP, Controller | Form 3 | Initial Statement of Beneficial Ownership of Securities | -- | -- | -- |
| Jan 03, 2017 |
Director
Trans History: 320
|
Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 7,000 | -- | -- |
| Dec 15, 2016 |
Director, President & CEO
Trans History: 404
|
Director, President & CEO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 250,000 | -- | -- |
| Dec 15, 2016 |
Director, President Regeneron Laboratori
Trans History: 628
|
Director, President Regeneron Laboratori | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 195,079 | -- | -- |
| Nov 07, 2016 |
Director, Chairman of the Board
Trans History: 742
|
Director, Chairman of the Board | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 76,895 | -- | -- |
| May 16, 2016 |
SVP Clinical Development & Reg
Trans History: 208
|
SVP Clinical Development & Reg | Form 4 | Bona fide gift | 2,459 | -- | -- |
| Apr 06, 2016 |
Director
Trans History: 381
|
Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 1,000 | -- | -- |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.